Base de dados : MEDLINE
Pesquisa : D27.505.954.557 [Categoria DeCS]
Referências encontradas : 43 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 5 ir para página              

  1 / 43 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28131079
[Au] Autor:Melvin SD; Habener LJ; Leusch FD; Carroll AR
[Ad] Endereço:Australian Rivers Institute, Griffith University, Southport, QLD 4222, Australia. Electronic address: s.melvin@griffith.edu.au.
[Ti] Título:H NMR-based metabolomics reveals sub-lethal toxicity of a mixture of diabetic and lipid-regulating pharmaceuticals on amphibian larvae.
[So] Source:Aquat Toxicol;184:123-132, 2017 Mar.
[Is] ISSN:1879-1514
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Pharmaceuticals are widely used for the treatment of various physical and psychological ailments. Due to incomplete removal during sewage treatment many pharmaceuticals are frequently detected in aquatic waterways at trace concentrations. The diversity of pharmaceutical contaminants and potential for complex mixtures to occur makes it very difficult to predict the toxicity of these compounds on wildlife, and robust methods are therefore needed to explore sub-lethal effects. Metabolic syndrome is one of the most widespread health concerns currently facing the human population, and various drugs, including anti-diabetic medications and lipid- and cholesterol-lowering fibrates and statins, are widely prescribed as treatment. In this study, we exposed striped marsh frog (Limnodynastes peronii) tadpoles to a mixture of the drugs metformin, atorvastatin and bezafibrate at 0.5, 5, 50 and 500µg/L to explore possible effects on growth and development, energy reserves (triglycerides and cholesterol), and profiles of small polar metabolites extracted from hepatic tissues. It was hypothesised that exposure would result in a general reduction in energy reserves, and that this would subsequently correspond with reduced growth and development. Responses differed from expected outcomes based on the known mechanisms of these compounds in humans, with no changes to hepatic triglycerides or cholesterol and a general increase in mass and condition with increasing exposure concentration. Deviation from the expected response patterns may be explained by differences in the receptivity or uptake of the compounds in non-mammalian species. Proton nuclear magnetic resonance ( H NMR) spectroscopy revealed evidence of broad metabolic dysregulation in exposed animals, and possible interaction between the solvent and mixture. Specifically, increased lactic acid and branched-chain amino acids were observed, with responses tending to follow a non-monotonic pattern. Overall, results demonstrate that a mixture of drugs commonly prescribed to treat human metabolic syndrome is capable of eliciting physiological and developmental effects on larval amphibians. Importantly, outcomes further suggest that it may not be possible to predict toxicological effects in non-target wildlife based on our knowledge of how these compounds act in humans.
[Mh] Termos MeSH primário: Anuros/fisiologia
Hipoglicemiantes/toxicidade
Larva/efeitos dos fármacos
Reguladores do Metabolismo de Lipídeos/toxicidade
Metaboloma/efeitos dos fármacos
Espectroscopia de Prótons por Ressonância Magnética
[Mh] Termos MeSH secundário: Animais
Metabolômica
Poluentes Químicos da Água/toxicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Lipid Regulating Agents); 0 (Water Pollutants, Chemical)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170417
[Lr] Data última revisão:
170417
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170129
[St] Status:MEDLINE


  2 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28003045
[Au] Autor:Fan ZX; Yang CJ; Yang J; Yang J
[Ad] Endereço:Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Yichang 443000, Hubei Province, China; Institute of Cardiovascular Diseases, China Three Gorges University, Yichang 443000, Hubei Province, China.
[Ti] Título:Stains: A novel therapy thought in myocardial ischemia reperfusion injury other than lipid lowering.
[So] Source:Int J Cardiol;229:10, 2017 Feb 15.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia
Traumatismo por Reperfusão Miocárdica/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Cardiotônicos/farmacologia
Modelos Animais de Doenças
Reguladores do Metabolismo de Lipídeos/farmacologia
Suínos
[Pt] Tipo de publicação:LETTER
[Nm] Nome de substância:
0 (Cardiotonic Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors); 0 (Lipid Regulating Agents)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161223
[St] Status:MEDLINE


  3 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27591119
[Au] Autor:Yamada K; Kobayashi H; Bo R; Purevsuren J; Mushimoto Y; Takahashi T; Hasegawa Y; Taketani T; Fukuda S; Yamaguchi S
[Ad] Endereço:Department of Pediatrics, Shimane University, Faculty of Medicine, Izumo, Shimane, Japan. Electronic address: k-yamada@med.shimane-u.ac.jp.
[Ti] Título:Efficacy of bezafibrate on fibroblasts of glutaric acidemia type II patients evaluated using an in vitro probe acylcarnitine assay.
[So] Source:Brain Dev;39(1):48-57, 2017 Jan.
[Is] ISSN:1872-7131
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: We evaluated the effects of bezafibrate (BEZ) on ß-oxidation in fibroblasts obtained from patients with glutaric acidemia type II (GA2) of various clinical severities using an in vitro probe (IVP) assay. METHODS: Cultured fibroblasts from 12 patients with GA2, including cases of the neonatal-onset type both with and without congenital anomalies (the prenatal- and neonatal-onset forms, respectively), the infantile-onset, and the myopathic forms, were studied. The IVP assay was performed by measuring acylcarnitines (ACs) in the cell culture medium of fibroblasts incubated with palmitic acid for 96h in the presence of 0-800µM BEZ using tandem mass spectrometry. RESULTS: The IVP assay showed that 100µM BEZ markedly reduced the level of palmitoylcarnitine (C16) in the neonatal-onset, infantile-onset, and myopathic forms of GA2, either increasing or maintaining a high level of acetylcarnitine (C2), which serves as an index of energy production via ß-oxidation. In the prenatal-onset form, although a small reduction of C16 was also observed in the presence of 100µM BEZ, the level of C2 remained low. At concentrations higher than 100µM, BEZ further decreased the level of ACs including C16, but a concentration over 400µM decreased the level of C2 in most cases. DISCUSSION: BEZ at 100µM was effective for all GA2 phenotypes except for the prenatal-onset form, as a reduction of C16 without deterioration of C2 is considered to indicate improvement of ß-oxidation. The effects of higher doses BEZ could not be estimated by the IVP assay but might be small or nonexistent.
[Mh] Termos MeSH primário: Bezafibrato/farmacologia
Carnitina/análogos & derivados
Fibroblastos/efeitos dos fármacos
Reguladores do Metabolismo de Lipídeos/farmacologia
Deficiência Múltipla de Acil Coenzima A Desidrogenase/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idade de Início
Carnitina/metabolismo
Sobrevivência Celular/efeitos dos fármacos
Células Cultivadas
Relação Dose-Resposta a Droga
Avaliação Pré-Clínica de Medicamentos
Ativadores de Enzimas/farmacologia
Feminino
Fibroblastos/metabolismo
Seres Humanos
Lactente
Recém-Nascido
Masculino
Deficiência Múltipla de Acil Coenzima A Desidrogenase/metabolismo
Palmitoilcarnitina/metabolismo
Receptores Ativados por Proliferador de Peroxissomo/agonistas
Pele/citologia
Pele/efeitos dos fármacos
Pele/metabolismo
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Enzyme Activators); 0 (Lipid Regulating Agents); 0 (Peroxisome Proliferator-Activated Receptors); 0 (acylcarnitine); 1935-18-8 (Palmitoylcarnitine); S7UI8SM58A (Carnitine); Y9449Q51XH (Bezafibrate)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170214
[Lr] Data última revisão:
170214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160904
[St] Status:MEDLINE


  4 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28058689
[Au] Autor:Krutetskaya ZI; Milenina LS; Naumova AA; Butov SN; Antonov VG; Nozdrachev AD
[Ad] Endereço:St. Petersburg State University, Universitetskaya nab. 7/9, St. Petersburg, 199034, Russia. z.krutetskaya@spbu.ru.
[Ti] Título:Methyl-ß-cyclodextrin inhibits Ca -responses induced by glutoxim and molixan in macrophages.
[So] Source:Dokl Biochem Biophys;471(1):390-392, 2016 Nov.
[Is] ISSN:1608-3091
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:Using Fura-2AM microfluorimetry, we have shown for the first time that methyl-ß-cyclodextrin, inducing cholesterol extraction from membranes and raft disruption, significantly inhibits glutoxim- and molixan-induced Ca -responses in rat peritoneal macrophages. The results suggest that intact rafts are necessary for signaling cascade induced by glutoxim or molixan and leading to intracellular Ca concentration increase in macrophages.
[Mh] Termos MeSH primário: Inosina/farmacologia
Reguladores do Metabolismo de Lipídeos/farmacologia
Macrófagos Peritoneais/efeitos dos fármacos
Moduladores de Transporte de Membrana/farmacologia
Oligopeptídeos/farmacologia
beta-Ciclodextrinas/farmacologia
[Mh] Termos MeSH secundário: Animais
Cálcio/metabolismo
Sinalização do Cálcio/efeitos dos fármacos
Sinalização do Cálcio/fisiologia
Cátions Bivalentes/metabolismo
Células Cultivadas
Colesterol/metabolismo
Combinação de Medicamentos
Interações Medicamentosas
Corantes Fluorescentes
Fluorometria
Fura-2/análogos & derivados
Macrófagos Peritoneais/metabolismo
Microdomínios da Membrana/efeitos dos fármacos
Microdomínios da Membrana/metabolismo
Ratos Wistar
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cations, Divalent); 0 (Drug Combinations); 0 (Fluorescent Dyes); 0 (Lipid Regulating Agents); 0 (Membrane Transport Modulators); 0 (Molixan); 0 (Oligopeptides); 0 (beta-Cyclodextrins); 0 (glutoxim); 0 (methyl-beta-cyclodextrin); 105344-37-4 (fura-2-am); 5A614L51CT (Inosine); 97C5T2UQ7J (Cholesterol); SY7Q814VUP (Calcium); TSN3DL106G (Fura-2)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170107
[St] Status:MEDLINE
[do] DOI:10.1134/S1607672916060041


  5 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27636924
[Au] Autor:Novgorodtseva TP; Denisenko YK; Antonyuk MV; Yubitskaya NS; Lobanova EG; Zhukova NV
[Ad] Endereço:Vladivostok Branch, Far Eastern Research Center for Physiology and Pathology of Respiration, Research Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russia.
[Ti] Título:[Blood fatty acids in the development and correction of metabolic syndrome].
[Ti] Título:Zhirnye kisloty krovi v formirovanii i korrektsii metabolicheskogo sindroma..
[So] Source:Ter Arkh;88(8):30-34, 2016.
[Is] ISSN:0040-3660
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:AIM: to investigate the composition of plasma fatty acids (FA) and red blood cells and the level of eicosanoids in patients with metabolic syndrome (MS) and to assess whether metabolic disturbances may be corrected during a cycle use of an ω-3 polyunsaturated fatty acid (PUFA). SUBJECTS AND METHODS: Examinations were made in 46 patients, including Group 1 (a control group) of 15 persons without MS components; Group 2 of 31 patients with MS, Group 3 of 16 MS patients who had taken an ω-3 PUFA for 6 months, and Group 4 of 15 MS patients who had received the drug for 12 months. The composition of plasma FA and red blood cells was analyzed on a gas-liquid chromatograph. An enzyme immunoassay was used to measure the serum levels of tumor necrosis factor-α (TNF-α) and eicosanoids (thromboxane B2, 6-keto-prostaglandin F1α, leukotriene B4). A biologically active additive from the king crab (Paralithodes camtschatica) hepatopancreas was used as a source of ω-3 PUFA. RESULTS: Having a higher proportion of linoleic and α-linolenic acids in the plasma, the patients were found to have decreased levels of ω-3 and ω-6 PUFAs (linoleic and α-linolenic, arachidonic, and eicosapentaenoic acids) and a larger proportion of Mead acid and saturated FAs (myristic and stearic acids) in the red blood cells, suggesting that that cellular blood FA transfer was impaired and FAs were absorbed by cells. Their serum samples showed the high levels of leukotriene B4, 6-keto-prostaglandin F1α, and thromboxane A2. The long-term (6- and 12-month) use of ω-3 PUFA from the king crab hepatopancreas had a positive impact in modifying the lipid FA composition of red blood cells and in eliminating deficiencies of physiologically important ω-3 and ω-6 PUFAs in the blood cells. CONCLUSION: The findings suggest that FAs and their metabolites play an important role in the pathogenesis of MS and that dietary ω-3 PUFA should be incorporated into a package of preventive and therapeutic measures for MS.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Eicosanoides/sangue
Eritrócitos
Ácidos Graxos Ômega-3/administração & dosagem
Ácidos Graxos/sangue
Síndrome Metabólica
[Mh] Termos MeSH secundário: Adulto
Animais
Anomuros
Doenças Cardiovasculares/etiologia
Monitoramento de Medicamentos/métodos
Eritrócitos/metabolismo
Eritrócitos/patologia
Ácidos Graxos/classificação
Feminino
Cromatografia Gasosa-Espectrometria de Massas/métodos
Seres Humanos
Reguladores do Metabolismo de Lipídeos/administração & dosagem
Masculino
Síndrome Metabólica/sangue
Síndrome Metabólica/complicações
Síndrome Metabólica/diagnóstico
Síndrome Metabólica/tratamento farmacológico
Meia-Idade
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Eicosanoids); 0 (Fatty Acids); 0 (Fatty Acids, Omega-3); 0 (Lipid Regulating Agents); 0 (Tumor Necrosis Factor-alpha)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160917
[St] Status:MEDLINE
[do] DOI:10.17116/terarkh201688830-34


  6 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27455321
[Au] Autor:Kang SJ; Choi BR; Kim SH; Yi HY; Park HR; Song CH; Ku SK; Lee YJ
[Ad] Endereço:The Medical Research Center for Globalization of Herbal Medicine, Daegu Haany University, 1, Haanydaero, Gyeongsan, Gyeongsangbuk-Do 38610, Korea. vegonia1@hanmail.net.
[Ti] Título:Selection of the Optimal Herbal Compositions of Red Clover and Pomegranate According to Their Protective Effect against Climacteric Symptoms in Ovariectomized Mice.
[So] Source:Nutrients;8(8), 2016 Jul 23.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:This study aimed to ascertain the optimal range of red clover dry extracts (RC) and dried pomegranate concentrate powder (PCP) to induce anti-climacteric effects. Thus, the dose ranges showing protective effect of mixed formulae consisting of RC and PCP were examined in ovariectomized mice. At 28 days after bilateral ovariectomy (OVX), mixed herbal compositions (RC:PCP = 1:1, 1:2, 1:4, 1:8, 2:1, 4:1, and 8:1) were administered orally, at 120 mg/kg once daily for 84 days. We evaluated that RC and PCP mixture attenuate OVX-caused obesity, hyperlipidemia, hepatic steatosis, and osteoporosis. Compared to OVX-induced control mice, body weight and abdominal fat weight in OVX-induced mice were significantly decreased, concomitantly with increase of uterus weight by RC:PCP mixture. Additionally, significant increases in serum estradiol levels were observed in all RC:PCP-treated mice. RC:PCP mixture also showed protective effect against OVX-induced hyperlipidemia, hepatic steatosis. Total body and femur mean bone mineral density (BMD), osteocalcin, bALP contents were effectively increased by RC:PCP mixture. Taken together, RC:PCP mixture (2:1, 1:1, and 4:1) has remarkable protective effects against the changes induced by OVX. In particular, RC:PCP mixture (2:1) shows the strongest effect and may be considered as a potential protective agent against climacteric symptoms.
[Mh] Termos MeSH primário: Suplementos Nutricionais
Modelos Animais de Doenças
Osteoporose Pós-Menopausa/prevenção & controle
Fitoestrógenos/administração & dosagem
Extratos Vegetais/administração & dosagem
Punicaceae/química
Trifolium/química
[Mh] Termos MeSH secundário: Animais
Animais não Endogâmicos
Fármacos Antiobesidade/administração & dosagem
Fármacos Antiobesidade/uso terapêutico
Biomarcadores/análise
Biomarcadores/sangue
Conservadores da Densidade Óssea/administração & dosagem
Conservadores da Densidade Óssea/uso terapêutico
Fígado Gorduroso/patologia
Fígado Gorduroso/prevenção & controle
Feminino
Frutas/química
Seres Humanos
Hiperlipidemias/sangue
Hiperlipidemias/patologia
Hiperlipidemias/prevenção & controle
Reguladores do Metabolismo de Lipídeos/administração & dosagem
Reguladores do Metabolismo de Lipídeos/uso terapêutico
Camundongos
Obesidade/sangue
Obesidade/patologia
Obesidade/prevenção & controle
Osteoporose Pós-Menopausa/sangue
Osteoporose Pós-Menopausa/patologia
Fitoestrógenos/uso terapêutico
Extratos Vegetais/uso terapêutico
Folhas de Planta/química
Organismos Livres de Patógenos Específicos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Obesity Agents); 0 (Biomarkers); 0 (Bone Density Conservation Agents); 0 (Lipid Regulating Agents); 0 (Phytoestrogens); 0 (Plant Extracts)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170317
[Lr] Data última revisão:
170317
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160726
[St] Status:MEDLINE


  7 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27447665
[Au] Autor:Bechor S; Zolberg Relevy N; Harari A; Almog T; Kamari Y; Ben-Amotz A; Harats D; Shaish A
[Ad] Endereço:The Bert W. Strassburger Lipid Center, Sheba Medical Center, Tel-Hashomer 5265601, Israel. sapirula@gmail.com.
[Ti] Título:9-cis ß-Carotene Increased Cholesterol Efflux to HDL in Macrophages.
[So] Source:Nutrients;8(7), 2016 Jul 19.
[Is] ISSN:2072-6643
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Cholesterol efflux from macrophages is a key process in reverse cholesterol transport and, therefore, might inhibit atherogenesis. 9-cis-ß-carotene (9-cis-ßc) is a precursor for 9-cis-retinoic-acid (9-cis-RA), which regulates macrophage cholesterol efflux. Our objective was to assess whether 9-cis-ßc increases macrophage cholesterol efflux and induces the expression of cholesterol transporters. Enrichment of a mouse diet with ßc from the alga Dunaliella led to ßc accumulation in peritoneal macrophages. 9-cis-ßc increased the mRNA levels of CYP26B1, an enzyme that regulates RA cellular levels, indicating the formation of RA from ßc in RAW264.7 macrophages. Furthermore, 9-cis-ßc, as well as all-trans-ßc, significantly increased cholesterol efflux to high-density lipoprotein (HDL) by 50% in RAW264.7 macrophages. Likewise, food fortification with 9-cis-ßc augmented cholesterol efflux from macrophages ex vivo. 9-cis-ßc increased both the mRNA and protein levels of ABCA1 and apolipoprotein E (APOE) and the mRNA level of ABCG1. Our study shows, for the first time, that 9-cis-ßc from the diet accumulates in peritoneal macrophages and increases cholesterol efflux to HDL. These effects might be ascribed to transcriptional induction of ABCA1, ABCG1, and APOE. These results highlight the beneficial effect of ßc in inhibition of atherosclerosis by improving cholesterol efflux from macrophages.
[Mh] Termos MeSH primário: Aterosclerose/prevenção & controle
HDL-Colesterol/secreção
Suplementos Nutricionais
Reguladores do Metabolismo de Lipídeos/uso terapêutico
Macrófagos Peritoneais/secreção
Regulação para Cima
beta Caroteno/análogos & derivados
[Mh] Termos MeSH secundário: Transportador 1 de Cassete de Ligação de ATP/agonistas
Transportador 1 de Cassete de Ligação de ATP/genética
Transportador 1 de Cassete de Ligação de ATP/metabolismo
Membro 1 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/agonistas
Membro 1 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/genética
Membro 1 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/metabolismo
Animais
Apolipoproteínas E/agonistas
Apolipoproteínas E/genética
Apolipoproteínas E/metabolismo
Aterosclerose/imunologia
Aterosclerose/metabolismo
Aterosclerose/patologia
Células Cultivadas
Clorófitas/química
HDL-Colesterol/sangue
HDL-Colesterol/metabolismo
Indução Enzimática
Reguladores do Metabolismo de Lipídeos/metabolismo
Macrófagos Peritoneais/imunologia
Macrófagos Peritoneais/metabolismo
Macrófagos Peritoneais/patologia
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Fitoplâncton/química
Células RAW 264.7
Receptores de LDL/genética
Receptores de LDL/metabolismo
Ácido Retinoico 4 Hidroxilase/química
Ácido Retinoico 4 Hidroxilase/genética
Ácido Retinoico 4 Hidroxilase/metabolismo
beta Caroteno/metabolismo
beta Caroteno/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ABCA1 protein, mouse); 0 (ABCG1 protein, mouse); 0 (ATP Binding Cassette Transporter 1); 0 (ATP Binding Cassette Transporter, Sub-Family G, Member 1); 0 (Apolipoproteins E); 0 (Cholesterol, HDL); 0 (Lipid Regulating Agents); 0 (Receptors, LDL); 01YAE03M7J (beta Carotene); EC 1.14.14.1 (Cyp26b1 protein, mouse); EC 1.14.14.1 (Retinoic Acid 4-Hydroxylase)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170317
[Lr] Data última revisão:
170317
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160723
[St] Status:MEDLINE


  8 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26868931
[Ti] Título:Two new lipid-regulating drugs.
[So] Source:Drug Ther Bull;54(2):18-21, 2016 Feb.
[Is] ISSN:1755-5248
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:â–¼Evolocumab (Repatha-Amgen Ltd) and â–¼alirocumab (Praluent-Sanofi) are the first in a novel class of lipid-regulating drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, to be licensed in the UK. Both drugs have marketing authorisation for the treatment of primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia and are administered by subcutaneous injection. Here we consider the evidence for evolocumab and alirocumab in the management of primary hypercholesterolaemia and dyslipidaemias.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/uso terapêutico
Dislipidemias/tratamento farmacológico
Hipercolesterolemia/tratamento farmacológico
Reguladores do Metabolismo de Lipídeos/uso terapêutico
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Lipid Regulating Agents); LKC0U3A8NJ (evolocumab); PP0SHH6V16 (alirocumab)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160213
[St] Status:MEDLINE
[do] DOI:10.1136/dtb.2016.2.0381


  9 / 43 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26525890
[Au] Autor:Yska JP; van der Meer DH; Dreijer AR; Eilander W; Apers JA; Emous M; Totté ER; Wilffert B; van Roon EN
[Ad] Endereço:Department of Clinical Pharmacy and Clinical Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR, Leeuwarden, The Netherlands. j.p.yska@znb.nl.
[Ti] Título:Influence of bariatric surgery on the use of medication.
[So] Source:Eur J Clin Pharmacol;72(2):203-9, 2016 Feb.
[Is] ISSN:1432-1041
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Bariatric surgery can influence the prevalence and incidence of comorbidities, as well as the pharmacokinetics of drugs. This might lead to changes in the use of drugs. This study aimed to assess the influence of bariatric surgery on the use of medication in patients before and after surgery, focusing on type, number of medications, and daily dosage. METHODS: In a retrospective and prospective observational study, drug dispensing data from pharmacies of patients undergoing their first bariatric surgery between January 2008 and September 2011 was collected. Dispensing data from 1 month before until 12 months after surgery was analyzed. Drugs were classified according to the WHO-ATC classification system. Dosages of drugs were compared using defined daily dose (DDD). RESULTS: Among 450 patients, 12 months after surgery, the mean number of drugs per patient for antidiabetics, drugs acting on the cardiovascular system, anti-inflammatory and antirheumatic drugs, and drugs for obstructed airway diseases decreased by, respectively, 71.3 % (95 % CI 57.2 to 85.4), 34.5 % (95 % CI 28.2 to 43.0), 45.5 % (95 % CI 13.3 to 72.6), and 33.1 % (95 % CI 15.3 to 53.2). Patients used lower median DDD of oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. CONCLUSIONS: For some major drug classes 12 months after bariatric surgery, the use of drugs decreases in terms of mean number per patient. A reduction in dose intensity was observed for oral antidiabetics, beta-blocking agents, and lipid-modifying drugs. Dispensing data from pharmacies may provide detailed information on the use of medications by patients after bariatric surgery.
[Mh] Termos MeSH primário: Cirurgia Bariátrica
Uso de Medicamentos/estatística & dados numéricos
Farmácias/estatística & dados numéricos
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos beta/uso terapêutico
Adulto
Anti-Inflamatórios/uso terapêutico
Antirreumáticos/uso terapêutico
Fármacos Cardiovasculares/uso terapêutico
Feminino
Seres Humanos
Hipoglicemiantes/uso terapêutico
Reguladores do Metabolismo de Lipídeos/uso terapêutico
Masculino
Meia-Idade
Países Baixos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Adrenergic beta-Antagonists); 0 (Anti-Inflammatory Agents); 0 (Antirheumatic Agents); 0 (Cardiovascular Agents); 0 (Hypoglycemic Agents); 0 (Lipid Regulating Agents)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170920
[Lr] Data última revisão:
170920
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151104
[St] Status:MEDLINE
[do] DOI:10.1007/s00228-015-1971-3


  10 / 43 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26548324
[Au] Autor:Barter PJ; Rye KA
[Ad] Endereço:School of Medical Sciences, The University of New South Wales, Sydney, New South Wales, Australia. Electronic address: p.barter@unsw.edu.au.
[Ti] Título:Targeting High-density Lipoproteins to Reduce Cardiovascular Risk: What Is the Evidence?
[So] Source:Clin Ther;37(12):2716-31, 2015 Dec 01.
[Is] ISSN:1879-114X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: This article reviews therapies that affect HDLs. FINDINGS: Lipid-modifying agents in current use (including statins, fibrates, and niacin) increase the concentration of HDL cholesterol to some extent. However, these agents have additional effects (beyond raising HDL) with the potential to reduce atherosclerotic cardiovascular disease (ASCVD) risk, making it difficult to determine (one way or the other) whether an increase in HDL concentration affects risk. New investigational approaches targeting HDLs include infusions of reconstituted HDLs, reinfusion of selectively delipidated plasma in which the concentration of pre-ß HDLs (the preferred acceptor of cell cholesterol) has been increased, and inhibitors of cholesteryl ester transfer protein (CETP). Positive results of the effects of reconstituted HDL infusions on coronary atheroma burden encourage further investigation of these agents. One small study on the effects of reinfusing selectively delipidated plasma has also provided results supporting additional development of this approach. CETP inhibitors are the most effective HDL-raising agents developed yet, with the ability to more than double the concentration of HDL cholesterol. They also reduce LDL cholesterol by up to 50%. Clinical outcome trials with the first 2 of these agents (torcetrapib and dalcetrapib) failed and, in the case of torcetrapib, treatment increased ASCVD events and increased both cardiovascular and noncardiovascular death. However, the subsequent discovery that torcetrapib had serious adverse effects unrelated to CETP inhibition meant that trials with this agent were unable to test the hypothesis that inhibiting CETP (or raising the level of HDL cholesterol) would translate into a reduction in ASCVD risk. The trial with dalcetrapib, a relatively weak inhibitor of CETP, was conducted in people soon after an acute coronary event when HDL functionality is impaired. The CETP inhibitor hypothesis will remain untested until completion of ongoing trials with CETP inhibitors that are more potent than dalcetrapib and that do not have the adverse effects of torcetrapib. IMPLICATIONS: Positive trials with reconstituted HDL infusions and reinfusions of selectively delipidated plasma will establish HDLs as important therapeutic targets. However, although a positive result in the trials with CETP inhibitors will establish CETP inhibition as a valid strategy to reduce ASCVD risk, it will not be possible to determine with certainty whether the reduction in risk is the consequence of effects on the HDL fraction or whether it is the result of CETP inhibitor-mediated reductions in LDL cholesterol.
[Mh] Termos MeSH primário: Doenças Cardiovasculares
Reguladores do Metabolismo de Lipídeos
Lipoproteínas HDL
[Mh] Termos MeSH secundário: Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Lipid Regulating Agents); 0 (Lipoproteins, HDL)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:151228
[Lr] Data última revisão:
151228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151110
[St] Status:MEDLINE



página 1 de 5 ir para página              
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde